• Featured Product
  • KD/KO Validated

P27; KIP1 Polyklonaler Antikörper

P27; KIP1 Polyklonal Antikörper für WB, IHC, IF/ICC, IF-P, FC (Intra), IP, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, IHC, IF/ICC, IF-P, FC (Intra), IP, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 25614-1-PBS

Synonyme

CDKN1B, P27, MEN1B, KIP1, Cyclin-dependent kinase inhibitor p27



Geprüfte Anwendungen

Produktinformation

25614-1-PBS bindet in WB, IHC, IF/ICC, IF-P, FC (Intra), IP, Indirect ELISA P27; KIP1 und zeigt Reaktivität mit human, Maus

Getestete Reaktivität human, Maus
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen P27; KIP1 fusion protein Ag22582
Vollständiger Name cyclin-dependent kinase inhibitor 1B (p27, Kip1)
Berechnetes Molekulargewicht 198 aa, 22 kDa
Beobachtetes Molekulargewicht 27 kDa
GenBank-ZugangsnummerBC001971
Gene symbol p27 Kip1/CDKN1B
Gene ID (NCBI) 1027
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.